Investors continue to mull mixed signals from the US Federal Reserve, continuing concerns about monetary policy tightening and a possible recession in the world’s largest economy
The BoE has spooked everyone by forecasting a peak in the rate above 13% this northern hemisphere autumn
Judge provided a temporary interdict against seizures until the industry’s internal appeal against the department’s decision that some labels are unlawful is complete.
The finance minister says the allegations are ‘fashioned to achieve narrow and selfish political ends’
Business Day TV spoke to Standard Bank CEO Sim Tshabalala
Spending allocations to increase to R812bn for the next three years, says finance minister
Food Safety Agency tells retailers and food producers it will seize vegan products with names that it says are for meat
The referendums may be held as late as January because Russian troops haven’t taken full control of the areas the Kremlin seeks to claim as its own
Anrich Nortjé took three wickets in the space of 10 balls to rip through the heart of the English batting
The luxury champagne lounge and cocktail bar is serving up a decadent high tea
London — Novo Nordisk, the Danish drugmaker, is exploring whether a new class of medicines that helps people lose weight and control diabetes also has potential in fighting Covid-19.
Research shows people afflicted by obesity and diabetes often fare worse in trying to overcome SARS-CoV-2. Initial analysis of electronic medical records shows that GLP-1 drugs, which help patients keep blood sugar levels in check, could be a “very meaningful therapy” in battling the illness, Novo chief scientific officer Mads Krogsgaard Thomsen said in an interview.
He pointed to evidence that the coronavirus attacks cells that produce insulin, the hormone needed by patients with diabetes.
“The early indication is that the GLP-1 class is actually beneficial in Covid-19,” he said. “That’s not unexpected because this is the class of agents that target the risk factors for bad Covid-19 outcomes.”
GLP-1 drugs include Novo’s Ozempic for diabetes and Saxenda for obesity. Sales of such drugs, which also include Eli Lilly’s Trulicity and AstraZeneca’s Bydureon, totalled more than $11bn last year, according to a report from Grand View Research.
Rush for treatments
Novo, the world’s biggest maker of diabetes drugs, is studying the role such medicines could play as researchers and governments rush to find treatments to combat the coronavirus. Last month, the US cleared use of convalescent plasma — which uses blood from people who have recovered from Covid-19 to help those currently infected — on an emergency basis for some cases.
That added to a growing list of therapies available to doctors. In May, regulators granted emergency authorisation to the Gilead Sciences antiviral drug remdesivir, while dexamethasone, a widely available generic corticosteroid anti-inflammatory drug, has shown life-saving promise.
Patients with Covid-19 can suffer from an inflammatory condition in which the immune system overreacts to the virus, causing damage that is worse than the infection itself. Studies show that semaglutide, the key ingredient in Ozempic, “dampens systemic inflammation” in people with diabetes and obesity, Thomsen said.
Novo is carrying out further studies and will make the results public if it can substantiate the preliminary data, he said.
Novo has bet on GLP-1 drugs, including Ozempic, forecast by analysts to generate $3.4bn in sales in 2020. Saxenda is expected to cross $1bn in sales this year. Earlier this year the company completed the final stage of tests for semaglutide in obesity.
“Obesity, hypertension and diabetes are big risk factors for bad outcomes,” said Thomsen. “But it is also so that the virus puts further stress on your cardiometabolic condition.”
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.